Presentations for the May 11, 2018 Joint Meeting of the Pediatric and Endocrinologic and Metabolic Drugs Advisory Committees
Smita B. Abraham, M.D.
Office of New Drugs, Division of Metabolism and Endocrinology Products
- Additional Safeguards for Children in Clinical Investigations, 21 CFR 50 Subpart D
Donna L. Snyder, M.D., F.A.A.P
FDA Office of Pediatric Therapeutics